Cecilia Bandini
Turin, 10126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Journal: Experimental hematology & oncology
Published: June 13, 2025
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Journal: Experimental hematology & oncology
Published: May 30, 2023
Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines.
Journal: Cancers
Published: February 27, 2023
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.
Journal: Haematologica
Published: March 31, 2022
Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.
Journal: Cancers
Published: March 22, 2021
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.
Journal: Cancers
Published: February 11, 2021
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Journal: Blood
Published: May 16, 2018
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.
Journal: Cancers
Published: November 27, 2017
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Journal: Oncotarget
Published: October 09, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026